Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
LymphomaLeukemia
Interventions
DRUG

Zevalin Radioimmunotherapy

Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg

DRUG

Rituximab

250 mg/m\^2 on day 1 and day 8

DRUG

Fludarabine

30 mg/m\^2/day for 3 days

DRUG

Cyclophosphamide

750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals

PROCEDURE

Allogeneic Stem Cell Transplantation

Allogeneic stem cell transplantation 2 days after chemotherapy

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER